XencorXNCR
XNCR
About: Xencor Inc is a clinical-stage biopharmaceutical company based in the United States. It focuses on discovering and developing engineered monoclonal antibody and other protein therapeutics to treat severe and life-threatening diseases such with unmet medical needs. The company uses its XmAb technology platform to create antibody product candidates such as XmAb5871 and XmAb7195. It also has a few pre-clinical stage candidates in its portfolio such as XmAb14045, XmAb662 among others. It earns its revenue from research and development collaborations and licenses of its internally developed drug candidates.
Employees: 280
0
Funds holding %
of 6,815 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
200% more funds holding in top 10
Funds holding in top 10: 1 [Q2] → 3 (+2) [Q3]
44% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 27
16% more capital invested
Capital invested by funds: $1.25B [Q2] → $1.45B (+$200M) [Q3]
5% more funds holding
Funds holding: 199 [Q2] → 209 (+10) [Q3]
3.96% less ownership
Funds ownership: 106.94% [Q2] → 102.98% (-3.96%) [Q3]
28% less repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 81
61% less call options, than puts
Call options by funds: $64K | Put options by funds: $163K
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$28
44%
upside
Avg. target
$32
65%
upside
High target
$37
90%
upside
4 analyst ratings
4 positive
100%
0 neutral
0%
0 negative
0%
Wells Fargo Eva Fortea Verdejo 20% 1-year accuracy 1 / 5 met price target | 90%upside $37 | Overweight Initiated | 12 Dec 2024 |
Piper Sandler Edward Tenthoff 29% 1-year accuracy 13 / 45 met price target | 54%upside $30 | Overweight Upgraded | 2 Dec 2024 |
BMO Capital Etzer Darout 24% 1-year accuracy 10 / 41 met price target | 74%upside $34 | Outperform Reiterated | 8 Nov 2024 |
JP Morgan Brian Cheng 22% 1-year accuracy 4 / 18 met price target | 44%upside $28 | Overweight Maintained | 7 Nov 2024 |
Financial journalist opinion
Positive
Zacks Investment Research
22 hours ago
Xencor (XNCR) Upgraded to Strong Buy: Here's What You Should Know
Xencor (XNCR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Positive
Zacks Investment Research
1 month ago
All You Need to Know About Xencor (XNCR) Rating Upgrade to Buy
Xencor (XNCR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Positive
Zacks Investment Research
1 month ago
Wall Street Analysts Think Xencor (XNCR) Could Surge 31.58%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 31.6% in Xencor (XNCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Neutral
Business Wire
1 month ago
Xencor to Participate at Upcoming Investor Conferences
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced that company management will participate at multiple upcoming investor conferences: Piper Sandler 36th Annual Healthcare Conference Date: Tuesday, December 3, 2024 Presentation Time: 2:00 p.m. ET / 11:00 a.m. PT Location: New York City 7th Annual Evercore HealthCONx Conference Date: Wedn.
Positive
Seeking Alpha
1 month ago
Xencor: Plamotamab NHL Data Leads To RA Program Advancement
Xencor's Phase 1 data using Plamotamab for the treatment of relapsed/refractory Non-Hodgkin's Lymphoma patients, expected at ASH 2024 Annual Meeting December 9th of 2024 at 6:00 to 8:00. Initiation of the phase 1b/2a study, using Plamotamab for the treatment of patients with multi-drug resistant Rheumatoid Arthritis, expected 1st half of 2025. XmAb657 is a long-acting CD19 X CD3 bispecific antibody being developed to target patients with autoimmune disorders; Phase 1 trial initiation for this program expected 2nd half of 2025.
Positive
Zacks Investment Research
1 month ago
Wall Street Analysts Believe Xencor (XNCR) Could Rally 53.53%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 53.5% in Xencor (XNCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Positive
Zacks Investment Research
2 months ago
Xencor (XNCR)'s Technical Outlook is Bright After Key Golden Cross
From a technical perspective, Xencor, Inc. (XNCR) is looking like an interesting pick, as it just reached a key level of support. XNCR's 50-day simple moving average crossed above its 200-day simple moving average, which is known as a "golden cross" in the trading world.
Negative
Zacks Investment Research
2 months ago
Xencor (XNCR) Reports Q3 Loss, Tops Revenue Estimates
Xencor (XNCR) came out with a quarterly loss of $0.71 per share versus the Zacks Consensus Estimate of a loss of $0.98. This compares to loss of $0.40 per share a year ago.
Neutral
Business Wire
2 months ago
Xencor Reports Third Quarter 2024 Financial Results
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today reported financial results for the third quarter ended September 30, 2024 and provided a review of recent business and clinical-stage program updates. “In September, we provided updates across our clinical pipeline of XmAb® bispecific T-cell engagers in oncology and introduced our new autoimmune p.
Neutral
Business Wire
2 months ago
Xencor Doses First Subject in Phase 1/2 Study of XmAb®942 in Development for Patients with Inflammatory Bowel Disease
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced that it has initiated dosing of healthy volunteers in the first-in-human study of XmAb®942, an investigational high-potency extended half-life anti-TL1A antibody. Xencor continues to expect initial data from the ongoing study during the first half of 2025. “An anti-TL1A antibody enginee.
Charts implemented using Lightweight Charts™